Hoag remains safe and ready to care for you. View COVID-19 information and updates.

A Leader in Valve Replacement: Hoag is First in OC to Complete 500 TAVR Procedures

By Stu News Newport

June 18, 2019

Hoag Memorial Hospital Presbyterian has announced the Jeffrey M. Carlton Heart & Vascular Institute has completed its 500th transcatheter aortic valve replacement (TAVR) procedure, an important alternative to open-heart surgery for patients requiring aortic valve replacement. Hoag was the first hospital in Orange County to offer TAVR and leads in volume and expertise.

The announcement reflects more than Hoag’s experience in this innovative treatment option; it is also indicative of the hospital’s leadership in improving quality of life, safety and positive outcomes.

“Hoag’s leadership in TAVR is just one example of the patient-centric focus that sets us apart in cardiovascular health,” said Aidan A. Raney, M.D., cardiothoracic surgeon and James & Pamela Muzzy Endowed Chair in Cardiovascular Surgery. “This milestone highlights our commitment to our patients and our community.”

More than 1.5 million people in the U.S. have aortic stenosis, a condition that can progress to restrict everyday activities, including walking short distances. Without intervention, most patients with severe aortic stenosis may die within two years. Unfortunately, for many high-risk patients, standard open-heart surgery is too risky.

Thanks to philanthropic support from Bob and Marjie Bennett and many other generous donors, Hoag began offering TAVR in 2012 to serve these patients, well before most hospitals in the nation.

“In 2012 Hoag took a leap of faith, but one that was researched and clinically proven to better care for our patients,” said Dr. Raney. “No other hospital in Orange County was offering TAVR, but we felt it was the right thing to do, to serve this patient population. We are incredibly proud of what our program is today, and the 500 patients we have helped.”

Hoag’s distinguished TAVR cardiology team at the Jeffrey M. Carlton Heart & Vascular Institute

A minimally invasive procedure, TAVR involves guiding a collapsible artificial valve into the heart using a catheter through a blood vessel in the leg or alternate site by an interventional cardiologist and cardiac surgeon. The artificial heart valve is then inserted across the patient’s own aortic valve where it immediately goes to work. This treatment option has provided hope and saved lives for people who would otherwise not qualify for surgery.

The largest volume cardiovascular program in Orange County, Hoag has established itself as a center for innovative and comprehensive cardiac care. “We are a leader in all therapies for aortic valve stenosis, including minimally invasive surgical approaches,” said Anthony Caffarelli, M.D., director of Hoag Cardiac Surgery and the Newkirk Family Endowed Chair in Aortic Care. “Hoag’s cardiac surgery program holds the highest rating award by The Society of Thoracic Surgeons for surgical aortic valve replacement, placing us in the top 10 percent in the country.”

After offering TAVR for high-risk patients for seven years, Hoag was selected to participate in the PARTNER 3 and Early TAVR trials, game-changing nationwide studies that expands the procedure to benefit low risk and asymptomatic patients as well.

Hoag contributed to what the American College of Cardiology referred to as “eye-popping” data involving 1,000 low-surgical-risk patients across 71 centers in the U.S. Participants were randomized to minimally invasive TAVR with the Edwards Lifesciences Sapien 3 valve or to open surgical aortic valve replacement, the standard procedure for aortic stenosis.

“Currently, TAVR is only offered to high-risk or intermediate-risk patients for open-heart surgery,” said Richard Haskell, M.D., interventional cardiologist. “These results are expected to expand TAVR as an option for select patients who are at low risk for surgical aortic valve replacement, allowing them to reap the benefits of valve replacement without undergoing open heart surgery.”

“Hoag not only is helping guide research for these procedures, but we have been providing it directly to our community with expertise, skill and efficiency,” said Subbarao Myla, M.D., program director for Hoag Cardiac Catheterization Labs. “Reaching our 500th case sends a message that Hoag is invested in providing the most advanced, pioneering treatments available to ensure the highest quality care for our patients.”

Hoag’s TAVR team includes:

–Anthony Caffarelli, M.D., Cardiothoracic Surgeon

–Jorge Castellanos, M.D., Interventional Cardiologist

–Cheng-Han Chen, M.D., Ph.D., Interventional Cardiologist

–Mahmoud Eslami, M.D., Interventional Cardiologist

–Richard Haskell, M.D., Interventional Cardiologist

–Subbarao Myla, M.D., Interventional Cardiologist

–Natesa Pandian, M.D., Cardiologist

–Aidan Raney, M.D., Cardiothoracic Surgeon

–Asad Shah, M.D., Cardiothoracic Surgeon

–Peggy Morley, DNP, ANP-BC, CCNS, TAVR Nurse Coordinator

–Humberto Wong, M.D., Radiologist

–Scott Williams, M.D., Radiologist

–Timothy Carpenter, M.D., Cardiac Anesthesiologist

–Alan Mouchawar, M.D., Cardiac Anesthesiologist

–Joseph Riggio, M.D., Cardiac Anesthesiologist

–Chaun Ren, M.D., Cardiac Anesthesiologist

–David Chavez, M.D., Cardiac Anesthesiologist

–Robert Kopel, M.D., Cardiac Anesthesiologist

–Rita Weise, NP, TAVR Nurse Coordinator

–Wendy J. Price, MSN, RN, Research Nurse Coordinator

–Jonathan Becerra, CCRP, Clinical Research Coordinator and TVT Registry Abstractor

To view the full article please visit Stu News Newport.

Additional coverage was featured in: